Angiogenesis is increased in multiple myeloma (MM) and has prognostic value. The anti-angiogenic agent, thalidomide, is effective in refractory MM and has shown marked synergy with dexamethasone. A randomized multi-institutional ECOG study will compare thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed MM. This proposal will utilize blood and bone marrow (BM) samples from this important study to test the central hypothesis that angiogenesis is important in MM and that anti-angiogenic therapy will be an effective way to treat MM. Preliminary data indicate that thalidomide can lead to decreased BM angiogenesis and VEGF expression. We hypothesize that thalidomide decreases the expression of VEGF and its receptors and inhibits BM angiogenesis, resulting in increased plasma cell apoptosis, decreased proliferation and tumor response. We also have data that support our hypothesis that thalidomide plus dexamethasone can inhibit mesenchymal progenitor cell (MPC) cytokine expression and differentiation. The proposal is organized into 3 specific aims: 1) To compare changes in BM angiogenesis and the level of expression of VEGF and its receptors before and after therapy and to correlate these measurements with response to therapy. 2) To determine the relationship between BM angiogenesis and MM cell VEGF expression with rates of myeloma cell apoptosis and proliferation and 3) To determine if thalidomide therapy inhibits expression of angiogenic cytokines/growth factors by BM MPC's and restores normal BM MPC function. For all 3 aims, our hypothesis is that the effects will be more pronounced with thalidomide plus dexamethasone than with dexamethasone alone. BM angiogenesis will be studied using immunohistochemical staining for CD34 and the rat aortic ring assay. Immunohistochemistry, in-situ hybridization, ELISA and RT-PCR assays will be used for the study of VEGF and its receptors and MPC cytokine expression. MPC growth and differentiation will be studied and compared to normal controls. Apoptosis will be measured using flow cytometric assays that gate on tumor cells; plasma cells in S-phase and circulating plasma cells will be estimated using slide based immunofluorescent assays. This study offers a unique opportunity to serially study tumor cells and the tumor microenvironment following potential anti-angiogenic therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA093842-03
Application #
6739049
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Wu, Roy S
Project Start
2002-04-15
Project End
2008-03-31
Budget Start
2004-04-01
Budget End
2008-03-31
Support Year
3
Fiscal Year
2004
Total Cost
$279,135
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Dispenzieri, Angela; Lacy, Martha Q et al. (2011) Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86:251-5
Kumar, Shaji K; Gertz, Morie A; Lacy, Martha Q et al. (2011) Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86:12-8
Kumar, Shaji K; Uno, Hajime; Jacobus, Susanna J et al. (2011) Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 118:4359-62
Dispenzieri, Angela; Dingli, David; Kumar, Shaji K et al. (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757-9
Dispenzieri, Angela; Katzmann, Jerry A; Kyle, Robert A et al. (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375:1721-8
Kumar, Shaji; Dispenzieri, Angela; Katzmann, Jerry A et al. (2010) Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 116:5126-9
Rajkumar, S Vincent; Jacobus, Susanna; Callander, Natalie S et al. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29-37
Kumar, Shaji K; Mikhael, Joseph R; Buadi, Francis K et al. (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095-110
Palumbo, A; Rajkumar, S V (2009) Treatment of newly diagnosed myeloma. Leukemia 23:449-56
Rajkumar, S Vincent (2008) Treatment of myeloma: cure vs control. Mayo Clin Proc 83:1142-5

Showing the most recent 10 out of 55 publications